Breo Ellipta vs Fasenra
A side-by-side look at two respiratory medications advertised on TV. Informational only — not medical advice.
| US Breo Ellipta | US Fasenra | |
|---|---|---|
| Generic name | fluticasone/vilanterol | benralizumab |
| Drug class | ICS/LABA Inhaler | IL-5 Receptor Antagonist (Biologic) |
| Treats | Asthma, COPD | Severe eosinophilic asthma |
| Category | Respiratory | Respiratory |
| Manufacturer | GSK | AstraZeneca |
| Year approved | 2013 | 2017 |
| FDA warning | No boxed warning | No boxed warning |
| Est. TV ad spend | $100M | $80M |
| Common side effects | Oral thrush, Throat irritation, Headache, Common cold symptoms | Headache, Sore throat, Allergic reactions, Injection site reactions |
Breo Ellipta
Frequently asked questions
Is Breo Ellipta or Fasenra better?
Neither is universally "better." Breo Ellipta (fluticasone/vilanterol) and Fasenra (benralizumab) are both used for respiratory, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Breo Ellipta and Fasenra?
Breo Ellipta is a ICS/LABA Inhaler made by GSK, while Fasenra is a IL-5 Receptor Antagonist (Biologic) made by AstraZeneca. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Breo Ellipta has the larger estimated TV advertising budget of the two.